47 results
8-K
EX-99.1
MRSN
Mersana Therapeutics Inc
5 Jan 24
Regulation FD Disclosure
8:06am
Healthcare Conference
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect … presentation from 42nd Annual J.P. Morgan Healthcare Conference at 2:15 p.m. Eastern Time (ET)/11:15 a.m. Pacific Time (PT) on January 11, 2024
PRE 14A
ipayl08w
18 Apr 22
Preliminary proxy
4:10pm
8-K
EX-99.1
9855 gm318po3p7rfk
9 Nov 21
Mersana Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
6:15am
8-K
EX-99.1
hg1oufj
6 Aug 21
Mersana Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
6:30am